Cash, cash equivalents and investments totaled $72.4M on March 31, compared to $56.3M on December 31, 2025. The balance at March 31 includes approximately $24M of the gross proceeds of $40M from the private placement that closed on April 1 with certain new and existing institutional and accredited investors. The March 31 balance plus the approximately $16M in gross proceeds received on April 1 extends the company’s cash runway to mid-2029.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCYX:
- Scynexis files to sell 87M shares of common stock for holders
- SCYNEXIS Director Steven Gilman Announces Board Retirement
- Scynexis: Strategic Pivot to Rare Disease With ADPKD Asset, Strengthened Balance Sheet, and Antifungal Optionality Support Buy Rating and $4 Target
- SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease
- SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline